Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.